Clinical trials: Resistance, Disease
Refractory Epilepsy
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal…
- Trial name
- NCT02866240
- Testing
- Cathodal Transcranial Direct Current Stimulation (tDCS).
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neuroelectrics Corporation
Metastatic Castration Resistant Prostate Cancer
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting.
- Trial name
- NCT02441517
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasms
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3…
- Trial name
- NCT01934790
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 16 sites in United States, Finland and 5 more
- Volunteers
- 45 people
- Sponsor
- Bayer
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Influenza
Influenza Resistance Information Study
This study will assist in the early detection of influenza resistant to antivirals and will monitor the clinical outcome of adults and children infected with influenza according to subtype and susceptibility.
- Trial name
- IRIS (NCT00884117)
- Testing
- Oseltamivir
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 4,561 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be…
- Trial name
- NCT02751918
- Testing
- Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 65 people
- Sponsor
- Bayer
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Treatment Resistant Depression
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
- Trial name
- NCT05624268
- Testing
- Psilocybin
- Where
- 40 sites in United States
- Volunteers
- 258 people
- Sponsor
- COMPASS Pathways
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Heart Failure, Volume Overload
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics.
- Trial name
- SAHARA (NCT04882358)
- Testing
- ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor
- Where
- 2 sites in Georgia
- Volunteers
- 24 people
- Sponsor
- Sequana Medical N.V.
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Metabolic Syndrome, Premature Aging
The Safety and Efficacy Study of RiaGev in Healthy Adults
This current randomized, double-blind, comparator-controlled, cross over study investigates the efficacy and safety of RiaGev™ via evaluation of NAD+, ATP, glucose, insulin, glutathione, and cortisol levels in healthy adults of…
- Trial name
- NCT04483011
- Testing
- RiaGev
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bioenergy Life Science, Inc.
Metabolic Syndrome
Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.
- Trial name
- OBEMINALE2 (NCT03692806)
- Testing
- Stablor
- Where
- 6 sites in France, Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- LNC THERAPEUTICS
Healthy Volunteers
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with…
- Trial name
- NCT00803972
- Testing
- rHuPH20, Insulin Human Injection, Insulin Lispro Injection
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus…
- Trial name
- CELLO-1 (NCT04179864)
- Testing
- Tazemetostat, Abiraterone/prednisone, Enzalutamide
- Where
- 24 sites in United States, Belgium and 1 more
- Volunteers
- 102 people
- Sponsor
- Epizyme, Inc.
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC…
- Conditions
- Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer
- Trial name
- NCT04504916
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00844844)
- Testing
- Eculizumab
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 1 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pouchitis
Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis
Phase 2 Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis
- Trial name
- FILLMORE (NCT04741087)
- Testing
- AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
- Where
- 34 sites in United States, Belgium and 8 more
- Volunteers
- 22 people
- Sponsor
- Applied Molecular Transport
Treatment Resistant Depression
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
- Trial name
- NCT01687478
- Testing
- Olanzapine, Fluoxetine
- Where
- 11 sites in China
- Volunteers
- 176 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.